Publications by authors named "N Solovieff"
Article Synopsis
- A study analyzed paired baseline and end-of-treatment circulating tumor DNA (ctDNA) samples from the MONALEESA trials to identify genetic changes in patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy (ET) or a placebo.
- The analysis included 523 samples, revealing 21 genes with significant alterations at end-of-treatment, particularly highlighting increased mutations in RB1 and SPEN in the ribociclib group, while ESR1 mutations were noted in both treatment arms.
- The findings suggest acquired genetic alterations related to treatment response and resistance, providing insights for future research on resistance mechanisms and potential systemic therapies following CDK4/6 inhibitors.
Article Synopsis
- In 2020, Novartis and the FDA began a 4-year collaboration to explore radio-genomics for predicting factors in HR+/HER- metastatic breast cancer.
- The partnership focuses on harnessing advanced analytics and AI to improve future scientific projects.
- The tutorial offers guidelines for conducting multi-omics research, emphasizing communication, data practices, and outlining a four-step process: plan, design, develop, and disseminate.
Article Synopsis
- - The MONALEESA-2, -3, -7 trials found that adding ribociclib to endocrine therapy significantly improved progression-free survival and overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
- - A study of tumor samples identified four intrinsic subtypes: luminal A (54.5%), luminal B (28.0%), HER2-enriched (14.6%), and basal-like (2.8%), with luminal A showing the best overall survival outcomes, while basal-like had the worst.
- - The analysis confirmed that patients with luminal and HER2E subtypes benefit from ribociclib, whereas those with basal-like subtype did not show significant benefits from the
Background: The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Using the largest pooled biomarker dataset of the CDK4/6 inhibitor ribociclib in ABC to date, we identified potential biomarkers of response to ribociclib.
Patients And Methods: Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing.
In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA sequencing alone, applying our model to 4324 oncology clinical cfDNA samples.
View Article and Find Full Text PDF